CureVac N.V. (NASDAQ: CVAC)’s stock price has gone rise by 13.00 in comparison to its previous close of 2.77, however, the company has experienced a 34.33% increase in its stock price over the last five trading days. Accesswire reported 2024-04-18 that TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
Is It Worth Investing in CureVac N.V. (NASDAQ: CVAC) Right Now?
Company’s 36-month beta value is 2.50.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CVAC is 91.60M, and currently, short sellers hold a 4.57% ratio of that floaft. The average trading volume of CVAC on May 06, 2024 was 793.98K shares.
CVAC’s Market Performance
The stock of CureVac N.V. (CVAC) has seen a 34.33% increase in the past week, with a 5.74% rise in the past month, and a -10.83% fall in the past quarter. The volatility ratio for the week is 8.23%, and the volatility levels for the past 30 days are at 7.15% for CVAC. The simple moving average for the past 20 days is 17.17% for CVAC’s stock, with a -41.28% simple moving average for the past 200 days.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the current year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at 4.23% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.68% of loss for the given period.
Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 8.23%, as shares surge +2.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.40% lower at present.
During the last 5 trading sessions, CVAC rose by +34.33%, which changed the moving average for the period of 200-days by -68.67% in comparison to the 20-day moving average, which settled at $2.67. In addition, CureVac N.V. saw -25.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- -5.2 for the present operating margin
- -1.45 for the gross margin
The net margin for CureVac N.V. stands at -4.85. The total capital return value is set at -0.46. Equity return is now at value -49.31, with -31.43 for asset returns.
Based on CureVac N.V. (CVAC), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.32. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -110.95.
Currently, EBITDA for the company is -249.55 million with net debt to EBITDA at 1.56. When we switch over and look at the enterprise to sales, we see a ratio of 5.45. The receivables turnover for the company is 1.48for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.57.
Conclusion
In a nutshell, CureVac N.V. (CVAC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
